Overview
Bifidobacterium longum subsp. infantis (commonly referred to as B. infantis) is a Gram-positive, anaerobic bacterium that represents the primary adapted colonizer of the breastfed infant gut. This subspecies possesses a unique metabolic capacity among bifidobacteria: the ability to fully metabolize human milk oligosaccharides (HMOs), the complex sugars that constitute the third-largest component of human breast milk. This specialized adaptation positions B. infantis as a keystone species in early-life microbiome development.
Despite its critical importance, B. infantis has become increasingly rare in Western infant populations, potentially due to widespread antibiotic use, Cesarean birth rates, and formula feeding practices. This decline has prompted significant research into supplementation strategies, with strains like EVC001 showing remarkable effects on reducing antibiotic resistance gene burden in the infant microbiome.
Classification
B. infantis is classified within the family Bifidobacteriaceae, phylum Actinomycetota (formerly Actinobacteria). It is a subspecies of Bifidobacterium longum, distinguished primarily by its expanded genetic capacity for HMO metabolism. The type strain is ATCC 15697 (= NCTC 11817 = DSM 20088 = JCM 1222), originally isolated from an infant intestine. Its complete genome has been sequenced and reveals a substantially larger HMO utilization gene cluster compared to other B. longum subspecies.
Key Characteristics
The defining characteristic of B. infantis is its unparalleled ability to internalize and metabolize all major classes of HMOs, including fucosylated, sialylated, and neutral core structures. While other bifidobacteria may partially degrade HMOs externally, B. infantis imports intact HMO molecules and processes them intracellularly, a strategy that prevents cross-feeding competitors and enables rapid, dominant colonization of the breastfed infant gut.
Research indicates that B. infantis colonization may significantly reduce the abundance of potentially harmful Proteobacteria in the infant gut, including Escherichia, Klebsiella, and Clostridioides difficile. Strain EVC001 has demonstrated particularly striking effects, with studies showing 87.5% fewer antibiotic resistance genes and greater than 93% reduction in Escherichia abundance in supplemented breastfed infants.
Health Significance
The health significance of B. infantis is centered on its foundational role in infant immune development and microbiome establishment. By dominating the breastfed infant gut, B. infantis may help program appropriate immune responses, stimulate secretory IgA production, and create a colonization environment that resists pathogenic invasion. Research suggests that early B. infantis colonization may have lasting effects on immune maturation that extend well beyond the breastfeeding period.
From a clinical perspective, strain CECT 7210 has demonstrated competitive inhibition of C. difficile and Cronobacter sakazakii in co-culture models, supporting its potential use in formula-fed infants who may lack natural B. infantis exposure. The reduction of antibiotic resistance genes by strain EVC001 is particularly significant in the context of global antimicrobial resistance concerns, suggesting that restoring B. infantis colonization could be a strategy for reducing the reservoir of resistance genes in early life.